Lupin has received final approval for its Clobetasol Propionate Spray, 0.05% from the United States Food and Drug Administration (USFDA) to market a generic version of Galderma Laboratories, L.P.'s Clobex Spray, 0.05%.
Clobetasol Propionate Spray, 0.05% had annual sales of around $30.5 million in the US (IQVIA MAT January 2018).
Lupin's Clobetasol Propionate Spray, 0.05% is the generic equivalent of Galderma Laboratories, L.P.'s Clobex Spray, 0.05%. It is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
